10-K/A: Zynex Amends 10-K, Reveals Tricare Payment Suspension and Internal Control Weaknesses Amidst Profit Decline

Zynex, Inc. filed an amended annual report detailing a temporary payment suspension from Tricare, a 10% staff reduction, and identified material weaknesses in internal controls, despite achieving revenue growth and its ninth consecutive profitable year.

Summary

• Net revenue increased by 4% to $192.4 million in 2024, up from $184.3 million in 2023, driven by a 16% growth in device orders.
• Net income decreased significantly to $3.0 million in 2024, down from $9.7 million in 2023, marking a $6.7 million decline.
• Operating cash flows decreased by 28%, or $5.0 million, to $12.7 million in 2024.
• The company is experiencing a temporary payment suspension from Tricare, which represents approximately 20-25% of its annual revenue.
• A staff reduction of approximately 10% was implemented in March 2025, primarily affecting corporate departments, expected to result in annual savings of approximately $35 million.
• Material weaknesses in internal controls over financial reporting were identified as of December 31, 2024, related to IT General Controls (ITGCs) and the valuation of certain accounts receivables.
• The company repurchased approximately $15.6 million worth of its common stock in 2024.
• General and administrative expenses increased by 24% to $60.4 million in 2024, primarily due to headcount growth in the ZMI reimbursement team, subcontractor expenses, and new product development at ZMS.
• Zynex Monitoring Solutions (ZMS) incurred operating expenses of $12.0 million in 2024 and $9.2 million in 2023, but has not generated any revenue to date.
• A lawsuit with Travelers Casualty Insurance Company of America was settled for $1.0 million in August 2024, with the action dismissed in December 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in net income and operating cash flow, a major payment suspension from Tricare leading to staff reductions, and identified material weaknesses in internal controls. While revenue growth and stock repurchases are positive, the operational and financial headwinds present considerable uncertainty and risk.

Positives

• Achieved a 16% increase in device orders in 2024, indicating strong product demand.
• Reported 4% revenue growth, reaching $192.4 million in 2024.
• Maintained profitability for the ninth consecutive year, with net income of $3.0 million in 2024.
• Demonstrated higher sales representative productivity, contributing to increased revenue per sales representative.
• Repurchased approximately $15.6 million worth of common stock in 2024, signaling confidence in company value and returning capital to shareholders.
• Recognized as a 'Best Company to Work For' by U.S. News & World Report and 'Top Workplaces', and ranked 9th in the Top 25 Medical Device Companies for 2024 by The Healthcare Technology Report.
• Received FDA 510(k) clearance for the CM-1500 Fluid Monitoring System in February 2020 and the wireless CM-1600 in June 2023.
• The M-Wave NMES device received FDA clearance in February 2024, expanding the product portfolio.

Negatives

• Net income decreased significantly to $3.0 million in 2024 from $9.7 million in 2023, a 69% decline.
• Operating cash flows decreased by 28% to $12.7 million in 2024 from $17.8 million in 2023.
• Working capital decreased to $58.3 million as of December 31, 2024, from $69.3 million as of December 31, 2023.
• A temporary payment suspension from Tricare, a government payer representing 20-25% of annual revenue, poses a significant risk to cash flow and revenue.
• Implemented a 10% staff reduction in March 2025 due to the Tricare payment suspension and lack of clarity on resolution timing.
• Identified material weaknesses in internal controls over financial reporting as of December 31, 2024, related to IT General Controls (ITGCs) and the valuation of certain accounts receivables.
• General and administrative expenses increased by 24% to $60.4 million in 2024, outpacing revenue growth.
• A $6.2 million allowance was placed on a group of older uncollectible receivables from a single payer in Q4 2023, reducing net revenue.

Risks

• Unfavorable global economic conditions, including inflationary pressures and geopolitical conflicts, could adversely affect business, financial condition, or results of operations.
• Rapid technological change could cause products to become obsolete, and failure to enhance product offerings may hinder competitiveness.
• Dependence on reimbursement from third-party payers, who are larger and have more resources, could lead to decreased or delayed revenues due to policy changes or payment denials.
• Failure to adequately identify and provide for amounts for resolution of repayment demands in the allowance for provider discounts could materially adversely affect results of operations and cash flows.
• Dependence on maintaining a Medicare Supplier Number; loss of which would materially and adversely affect business, financial condition, results of operations, and cash flows.
• Periodic reviews and billing audits from governmental and private payers could result in required refunds, fines, penalties, loss of participation rights, or damage to reputation.
• Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect product acceptance and reduce revenues.
• Inability to maintain necessary reimbursement codes (e.g., HCPCS codes) could affect revenues and physician prescription rates.
• Future changes in coverage and reimbursement policies or reductions in rates by third-party payers could adversely affect business and results of operations.
• Significant estimating risks associated with revenue, refund liabilities, accounts receivable, and provider discounts could impact revenue recognition timing, cash collections, or lead to financial restatements.
• Tax laws and regulations require compliance efforts that can increase costs, and changes could impact financial results.
• The impact of healthcare reform legislation (e.g., PPACA, IRA) and other changes in the healthcare industry on the business is currently unknown but may be detrimental.
• Subject to United States federal and state healthcare fraud and abuse and false claims laws and regulations, with increased prosecutions and potential for substantial penalties, fines, or exclusion from government programs.
• Litigation and other claims (e.g., employee, commercial, intellectual property, product liability) could distract management, result in significant liability, or harm the brand.
• Hospitals and clinicians may not buy, prescribe, or use products in sufficient numbers due to cost, financial inability, adverse patient events, lack of education/training, malfunctions, or reimbursement uncertainty.
• Competition from larger companies with greater financial and other resources could result in fewer orders, reduced gross margins, and loss of market share.
• Failure to keep pace with the latest technological changes could result in decreased revenues.
• Reliance on sole or limited suppliers for essential product components could lead to cost increases or supply disruptions.
• A third-party manufacturer's inability to produce components on time or to specifications could result in lost revenue.
• Cost increases or disruptions in the supply of raw materials or other components (e.g., semiconductor chips) could adversely affect business.
• Replacing manufacturers could increase expenses and cost of goods, resulting in lower profit margins.
• Sales fluctuations and employee turnover, particularly of key personnel like Mr. Sandgaard, may adversely affect the business.
• Need to maintain insurance coverage (e.g., product liability), which could become very expensive or have limited availability.
• Product recalls, even after regulatory clearance, would harm reputation and business.
• Continued incurrence of research and development, sales and marketing, and general and administrative expenses may adversely affect potential profits and liquidity.
• Substantial costs could be incurred defending against claims of intellectual property infringement.
• Inability to protect trademarks, trade secrets, and other intellectual property rights important to the business.
• Failure to protect the privacy, integrity, and security of customer information (including Protected Health Information) could harm business, reputation, and results of operations.
• Cyber-attacks and security vulnerabilities could lead to reduced revenue, increased costs, liability claims, or harm to competitive position.
• Identified material weaknesses in internal controls over financial reporting may result in material misstatements or failure to meet periodic reporting obligations.
• Expansion of operations and sales internationally may subject the company to additional risks, including unexpected events and compliance challenges.
• Acquisition of other companies could require significant management attention, disrupt business, dilute stockholder value, and adversely affect operating results if not successfully integrated.
• Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect reported results of operations.
• The conversion feature of convertible senior notes, if triggered, may adversely affect financial condition and operating results, potentially requiring cash settlement or reclassification as a current liability.
• Sales of significant amounts of shares held by Mr. Sandgaard, or the prospect of these sales, could adversely affect the market price of common stock.

Future Outlook

The company anticipates submitting its NiCO CO-Oximeter to the FDA for clearance in Q1 2025. A staff reduction and other expense adjustments made in late 2024 and early 2025 are expected to result in approximately $35 million in annual savings. Management believes the pain management business remains solid with significant growth potential and plans approximately $1.5 million in capital expenditures during 2025.

Management Comments

• "We are confident that long-term, our pain management business is still solid with significant growth potential."
• "Although these processes are never easy, it is critical for us to be prudent and conservative in adapting to external changes and execute these expense adjustments immediately."

Industry Context

Zynex operates in the medical device industry, primarily focusing on home electrotherapy for pain management and rehabilitation, a market estimated at $500 million to $1 billion annually in the U.S. The company positions its non-pharmacological pain relief products as an alternative to opioids, addressing the ongoing opioid epidemic. Zynex Monitoring Solutions (ZMS) is developing non-invasive multi-parameter patient monitoring devices, including laser pulse oximetry and total hemoglobin products, aiming to address unmet needs in the market for safer surgeries and patient monitoring.

Corporate Governance

Legal Proceedings

• Settled a complaint filed by Travelers Casualty Insurance Company of America on behalf of the State of California, alleging violations of the California Insurance Frauds Prevention Act (IFPA) for alleged false billing practices. The settlement amount was $1.0 million, resolving claims and establishing a billing protocol for future claims. The action was dismissed with prejudice on December 13, 2024.
• Currently responding to investigative demands, subpoenas, and formal document and records requests from various government organizations, including the Department of Justice, Department of Health and Human Services-Office of Inspector General, California Department of Insurance, and Colorado Attorney General. These investigations could lead to government actions, fines, penalties, or other sanctions.

Related Party Transactions

• On May 10, 2023, the company purchased 300,000 common shares from Thomas Sandgaard, Chairman, President, Chief Executive Officer, and Principal Executive Officer, for $2.9 million.
• On June 13, 2023, the company purchased an additional 300,000 common shares from Thomas Sandgaard for $2.6 million.

Stakeholder Impact

• Shareholders: Face potential dilution from future capital raises, stock price volatility due to financial performance and operational challenges, but also benefit from ongoing stock repurchase programs.
• Employees: Experienced a 10% staff reduction in March 2025 due to financial adjustments, but the company emphasizes competitive pay, benefits, and development programs for remaining staff.
• Customers/Patients: Continued support for existing and new patients despite the Tricare payment suspension, ensuring access to pain management devices and supplies.
• Suppliers: Potential for disruptions or increased costs due to reliance on sole or limited suppliers for key components like semiconductor chips.
• Creditors: The company has outstanding convertible senior notes, and potential reclassification of these notes as current liabilities could impact short-term financial obligations.

Next Steps

• Attend a meeting with Tricare in April (2025) to discuss payment reinstatement.
• Continue to support both existing and new patients receiving prescriptions, as directed by Tricare.
• Continue developing and implementing remediation plans to address identified material weaknesses in internal control over financial reporting.
• Anticipate submitting the NiCO CO-Oximeter to the FDA for clearance in Q1 2025.
• Utilize ongoing enrollments at Duke University for future development of ZMS products.
• File the definitive proxy statement relating to its 2025 annual meeting of stockholders within 120 days after December 31, 2024.
• Continue to hire field sales representatives, focusing on quality and increasing performance management standards.

Key Dates

Recommendation

While Zynex demonstrated revenue growth and continued profitability in 2024, the significant decline in net income and operating cash flow, coupled with the temporary payment suspension from Tricare (a major revenue source), introduces substantial uncertainty. The announced 10% staff reduction and identified material weaknesses in internal controls further highlight operational and financial challenges. The ongoing government investigations add another layer of risk. Given these mixed signals and the high degree of uncertainty surrounding key revenue streams and internal controls, a 'hold' recommendation is appropriate. Investors should monitor the resolution of the Tricare issue, the effectiveness of remediation efforts for internal control weaknesses, and the outcome of government investigations before considering further investment.

Keywords

Medical Devices, Electrotherapy, Pain Management, SEC Filing, 10-K/A, Financial Performance, Tricare, Internal Controls, Risk Factors, Healthcare Industry, FDA Clearance, Stock Repurchase, Zynex Medical, Zynex Monitoring Solutions, Corporate Governance, Legal Proceedings, Reimbursement, Patient Monitoring, NeuroMove, NexWave, NiCO, HemeOx